Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOUR™)

• Main Authors: Adam M. Bressler, Ali A. Hassoun, Louis D. Saravolatz, Valerie Ravenna, Chris N. Barnes, Bibiana Castaneda-Ruiz
• Format: Article
• Language: English
• Published: Adis, Springer Healthcare 2019-11-01
• Series: Drugs - Real World Outcomes
• Online Access: http://link.springer.com/article/10.1007/s40801-019-00165-8

Abstract Background Telavancin—a lipoglycopeptide antibacterial agent active against Gram-positive pathogens including methicillin-sensitive and -resistant Staphylococcus aureus (MRSA)—is approved in the USA for once-daily intravenous use. This registry study captured patient characteristics, prescribing patterns, and treatment outcomes associated with telavancin use in real-world clinical practice. Objective This prospective, multicenter, observational study will characterize current real-world practice patterns for the use of telavancin in the USA by describing demographic and clinical conditions, examining the process of care and rationale for use, and describing the clinical effectiveness and selected safety outcomes among patients treated with telavancin. Methods The Telavancin Observational Use Registry (TOUR™) is an observational multicenter registry study. Clinical data—including patient demographics, pathogens, telavancin dosing and treatment duration, and adverse events—along with investigators’ assessments of outcome, were collected through retrospective medical chart review. Results Data from 1063 patients were collected from 45 US sites. Of these patients, 29.4% were ≥ 65 years of age [mean age ± standard deviation, 55.2 ± 15.4 years; median age (interquartile range), 57.0 (46.0–66.0)], 53.4% were male, and 83.4% were White. The primary infections in these patients included complicated skin and skin-structure infection (48.7%), bone and joint infections (27.4%), bacteremia and endocarditis (14.2%), and lower respiratory tract infections (8.5%). The predominant pathogen identified was MRSA (37.7%). The mean telavancin dose and duration of treatment were 741.7 ± 194.3 mg and 17 ± 17 days, respectively. Of the 964 (90.7%) patients for whom an end-of-treatment assessment was available, 77.7% had a positive clinical response, 10.1% failed treatment, and 12.2% had indeterminate outcomes. Conclusions Real-world data collected from the TOUR study show once-daily telavancin is being used for the treatment of a variety of Gram-positive infections with generally positive clinical outcomes.